2,5-Diketopiperazines (DKPs) : Promising Scaffolds for Anticancer Agents
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
2,5-Diketopiperazine (2,5-DKP) derivatives represent a family of secondary metabolites widely produced by bacteria, fungi, plants, animals, and marine organisms. Many natural products with DKP scaffolds exhibited various pharmacological activities such as antiviral, antifungal, antibacterial, and antitumor. 2,5-DKPs are recognized as privileged structures in medicinal chemistry, and compounds that incorporate the 2,5-DKP scaffold have been extensively investigated for their anticancer properties. This review is a thorough update on the anti-cancer activity of natural and synthesized 2,5-DKPs from 1997 to 2022. We have explored various aspects of 2,5-DKPs modifications and summarized their structure-activity relationships (SARs) to gain insight into their anticancer activities. We have also highlighted the novel approaches to enhance the specificity and pharmacokinetics of 2,5-DKP-based anticancer agents.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Current pharmaceutical design - (2024) vom: 09. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Goher, Shaimaa [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anticancer Activities |
|---|
| Anmerkungen: |
Date Revised 12.02.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.2174/0113816128291798240201112916 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368332047 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368332047 | ||
| 003 | DE-627 | ||
| 005 | 20240213233029.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240213s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/0113816128291798240201112916 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1291.xml |
| 035 | |a (DE-627)NLM368332047 | ||
| 035 | |a (NLM)38343054 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Goher, Shaimaa |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a 2,5-Diketopiperazines (DKPs) |b Promising Scaffolds for Anticancer Agents |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 12.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a 2,5-Diketopiperazine (2,5-DKP) derivatives represent a family of secondary metabolites widely produced by bacteria, fungi, plants, animals, and marine organisms. Many natural products with DKP scaffolds exhibited various pharmacological activities such as antiviral, antifungal, antibacterial, and antitumor. 2,5-DKPs are recognized as privileged structures in medicinal chemistry, and compounds that incorporate the 2,5-DKP scaffold have been extensively investigated for their anticancer properties. This review is a thorough update on the anti-cancer activity of natural and synthesized 2,5-DKPs from 1997 to 2022. We have explored various aspects of 2,5-DKPs modifications and summarized their structure-activity relationships (SARs) to gain insight into their anticancer activities. We have also highlighted the novel approaches to enhance the specificity and pharmacokinetics of 2,5-DKP-based anticancer agents | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Anticancer Activities | |
| 650 | 4 | |a DKP | |
| 650 | 4 | |a Marine Fungus | |
| 650 | 4 | |a Natural Alkaloids | |
| 650 | 4 | |a Natural Products | |
| 700 | 1 | |a Abdrabo, Wessam S |e verfasserin |4 aut | |
| 700 | 1 | |a Veerakanellore, Giri Babu |e verfasserin |4 aut | |
| 700 | 1 | |a ELgendy, Bahaa |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current pharmaceutical design |d 1998 |g (2024) vom: 09. Feb. |w (DE-627)NLM095430172 |x 1873-4286 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:09 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/0113816128291798240201112916 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 09 |c 02 | ||